ループス腎炎の参加者における治験治療中止の有無にかかわらず、イアナルマブの有効性と安全性に関する第III相延長試験(SIRIUS-LN延長) (SIRIUS-LN ext)
CVAY736K12301コア研究(SIRIUS-LN延長)における治験治療を完了したループス腎炎の成人参加者を対象に、治験治療中止の有無にかかわらずイアナルマブの有効性と安全性を評価する非盲検延長試験
The purpose of this up to 6-year extension study is the evaluation of the efficacy and safety
- after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response [CRR] or partial renal response [PRR]) on double-blind treatment at the end of the SIRIUS-LN core study, and
- of open-label ianalumab 300 mg treatment in patients who, at the end of the SIRIUS-LN core study, were either already receiving ianalumab open-label treatment or did not meet CRR/PRR criteria on double-blind treatment at the end of the SIRIUS-LN core study.
調査の概要
詳細な説明
The SIRIUS-LN extension study is an up to 6-year open-label extension study for participants who have completed the treatment periods (blinded Treatment Period-1 and blinded Treatment Period-2) of the SIRIUS-LN core study on double-blind or open-label study treatment.
Investigators will use their clinical judgment to decide if it is beneficial for participants to continue with the extension study. In this extension study participants who achieve CRR or PRR status at Week 140 will be withdrawn from study treatment and will maintain the SoC medication as required. These up to 6 additional years in the extension study will allow to measure sustained remission, flares and safety off-study treatment. However, in the event of renal flares during the extension study, these participants who withdraw study treatment will have the option to receive open-label ianalumab.
研究の種類
入学 (推定)
段階
- フェーズ 3
アクセスの拡大
連絡先と場所
研究連絡先
- 名前:Novartis Pharmaceuticals
- 電話番号:1-888-669-6682
- メール:novartis.email@novartis.com
研究連絡先のバックアップ
- 名前:Novartis Pharmaceuticals
- 電話番号:+41613241111
- メール:novartis.email@novartis.com
研究場所
-
-
New York
-
Orchard Park、New York、アメリカ、14127
- 募集
- Circuit Clinical
-
主任研究者:
- Isha Gupta
-
コンタクト:
- Gabriella Demelo
- メール:gdemelo@circuitclinical.com
-
-
-
-
-
Guatemala City、グアテマラ、01010
- 募集
- Novartis Investigative Site
-
-
Departamento de Guatemala
-
Guatemala City、Departamento de Guatemala、グアテマラ、01011
- 募集
- Novartis Investigative Site
-
-
Departamento de Quetzaltenango
-
Quetzaltenango、Departamento de Quetzaltenango、グアテマラ、09001
- 募集
- Novartis Investigative Site
-
-
-
-
Antioquia
-
Medellín、Antioquia、コロンビア、050001
- 募集
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla、Atlántico、コロンビア、080020
- 募集
- Novartis Investigative Site
-
-
-
-
-
Singapore、シンガポール、169608
- 募集
- Novartis Investigative Site
-
-
Singapore
-
Singapore、Singapore、シンガポール、308433
- 募集
- Novartis Investigative Site
-
-
-
-
-
Barcelona、スペイン、08035
- 募集
- Novartis Investigative Site
-
-
-
-
-
Bangkok、タイ、10400
- 募集
- Novartis Investigative Site
-
Bangkok、タイ、10330
- 募集
- Novartis Investigative Site
-
Bangkok、タイ、10700
- 募集
- Novartis Investigative Site
-
Chiang Mai、タイ、50200
- 募集
- Novartis Investigative Site
-
-
Hat Yai
-
Songkhla、Hat Yai、タイ、90110
- 募集
- Novartis Investigative Site
-
-
-
-
-
Olomouc、チェコ、779 00
- 積極的、募集していない
- Novartis Investigative Site
-
Prague、チェコ、128 00
- 募集
- Novartis Investigative Site
-
-
-
-
-
Budapest、ハンガリー、1097
- 募集
- Novartis Investigative Site
-
-
-
-
-
Grenoble、フランス、38043
- 募集
- Novartis Investigative Site
-
-
-
-
Espírito Santo
-
Vitória、Espírito Santo、ブラジル、29055-450
- 募集
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、ブラジル、40150-150
- 募集
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte、Minas Gerais、ブラジル、30150-221
- 募集
- Novartis Investigative Site
-
-
Pernambuco
-
Recife、Pernambuco、ブラジル、50740-900
- 募集
- Novartis Investigative Site
-
-
São Paulo
-
Santo André、São Paulo、ブラジル、09090-790
- 募集
- Novartis Investigative Site
-
-
-
-
VNM
-
Ho Chi Minh City、VNM、ベトナム、700000
- 募集
- Novartis Investigative Site
-
-
-
-
Kuala Lumpur
-
Kuala Lumpur、Kuala Lumpur、マレーシア、50586
- 募集
- Novartis Investigative Site
-
-
Sarawak
-
Sibu、Sarawak、マレーシア、96000
- 募集
- Novartis Investigative Site
-
-
-
-
-
Oaxaca City、メキシコ、68020
- 募集
- Novartis Investigative Site
-
Querétaro、メキシコ、76070
- 募集
- Novartis Investigative Site
-
-
Guanajuato
-
León、Guanajuato、メキシコ、37160
- 募集
- Novartis Investigative Site
-
-
-
-
-
Bucharest、ルーマニア、022328
- 募集
- Novartis Investigative Site
-
-
-
-
-
Beijing、中国、100034
- 募集
- Novartis Investigative Site
-
Chongqing、中国、400038
- 募集
- Novartis Investigative Site
-
Guangzhou、中国、510280
- 募集
- Novartis Investigative Site
-
Guangzhou、中国、510080
- 募集
- Novartis Investigative Site
-
Shanghai、中国、200080
- 募集
- Novartis Investigative Site
-
Shanghai、中国、200040
- 募集
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510000
- 募集
- Novartis Investigative Site
-
Shantou、Guangdong、中国、515000
- 積極的、募集していない
- Novartis Investigative Site
-
Shenzhen、Guangdong、中国、518037
- 募集
- Novartis Investigative Site
-
-
Guangxi
-
Liuzhou、Guangxi、中国、545005
- 募集
- Novartis Investigative Site
-
-
Hubei
-
Wuhan、Hubei、中国、430060
- 募集
- Novartis Investigative Site
-
-
Jilin
-
Changchun、Jilin、中国、130041
- 募集
- Novartis Investigative Site
-
-
Liaoning
-
Shenyang、Liaoning、中国、110004
- 募集
- Novartis Investigative Site
-
-
Shandong
-
Binzhou、Shandong、中国、256603
- 募集
- Novartis Investigative Site
-
-
Zhejiang
-
Ningbo、Zhejiang、中国、315016
- 募集
- Novartis Investigative Site
-
-
-
-
-
Taichung、台湾、40447
- 募集
- Novartis Investigative Site
-
-
-
-
-
Seoul、韓国、06591
- 募集
- Novartis Investigative Site
-
Seoul、韓国、03722
- 募集
- Novartis Investigative Site
-
Seoul、韓国、04763
- 募集
- Novartis Investigative Site
-
-
Gyeonggi-do
-
Suwon、Gyeonggi-do、韓国、16499
- 募集
- Novartis Investigative Site
-
-
-
-
-
Tuenmen、香港、999077
- 募集
- Novartis Investigative Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Signed informed consent prior to participation in the extension study.
- Participants must have participated in the SIRIUS-LN core study and must have completed the entire treatment up to Week 144 on double-blind or open label study treatment.
Exclusion Criteria:
- Use of prohibited therapies
- Pregnant or nursing (lactating) women.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし:Study Treatment Withdrawal (cohort 1)
(Cohort 1): Study Treatment-Withdrawal group. Participants who received blinded study treatment in the core study and achieve CRR or PRR at Week 140 in the core study will enter the extension study and discontinue study treatment while maintaining standard of care (SoC) medication, as required. If renal flare criteria are met, participants will be eligible to receive open-label ianalumab. |
|
|
実験的:Open-Label Ianalumab (cohort 2)
(Cohort 2): Open-Label Ianalumab group: Participants who received blinded study treatment throughout the core study and did not achieve CRR or PRR at Week 140 of the core study, or who had switched to open-label ianalumab during the core study, will be eligible or will continue to receive open-label ianalumab in the extension study. |
Ianalumab (VAY736) is a human monoclonal antibody (mAb) of the IgG1/κ-class, directed against B cells and binding to BAFF receptor (BAFF-R).
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cohort 1: Time to renal flare, increase in immunosuppressive medication, or death
時間枠:Between Week 144E1 and EOS (up to Week 456)
|
Cohort 1: To estimate the time to renal flare, increase in immunosuppressive medication, or death following study treatment withdrawal in participants who completed the SIRIUS-LN core study on double-blind treatment and achieved CRR or PRR at Week 140 of the core study |
Between Week 144E1 and EOS (up to Week 456)
|
|
Cohort 2: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
時間枠:From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
|
Number of participants with AEs and SAEs, including changes in vital signs and clinical laboratory measurements qualifying and reported as AEs. |
From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cohort 2: Incidence and titer of anti-ianalumab antibodies in serum (ADA assay)
時間枠:from Week 144E1 up to Week 456
|
To assess immunogenicity to ianalumab in Cohort 2 |
from Week 144E1 up to Week 456
|
|
Cohort 2: Ianalumab concentration in serum using a validated ELISA
時間枠:from Week 144E1 up to Week 456
|
To assess pharmacokinetics of ianalumab in Cohort 2 |
from Week 144E1 up to Week 456
|
|
Cohort 1: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
時間枠:From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
|
Number of participants with AEs and SAEs, including changes in vital signs and clinical laboratory measurements qualifying and reported as AEs. |
From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Novartis Pharmaceuticals、Novartis Pharmaceuticals
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- CVAY736K12301E1
- 2024-515280-60-00 (その他の識別子:EU CTR)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。